METHOD FOR DETERMINING THE RISK OF RECURRENCE OF SUPERFICIAL BLADDER CANCER AFTER SURGICAL TREATMENT Russian patent published in 2018 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to determine the risk of recurrence of superficial bladder cancer after surgical treatment. For this purpose, the first morning urine sample of a patient with bladder cancer T1N0M0, TaN0M0 or TisN0M0. Portion was centrifuged at 2,000 rpm for 20 min to precipitate the cell elements. After this, the supernatant was drained, 2 ml of PBS was added to the pellet. Then, resuspension was carried out by pipetting for 1–2 min and centrifuged at 2,000 rpm for 10 min. This procedure for washing the cell pellet was carried out twice. Supernatant was then decanted, 0.5 ml of PBS was added to the pellet. Resulting cell suspension was then resuspended for 1–2 minutes. To this, monoclonal antibodies to CD13 labeled with phycoerythrin in a volume of 20 mcl were added. Stirred on a personal vortex for 20 seconds. Monoclonal antibodies to CD45 labeled with fluorescein with isothiocyanate in a volume of 20 mcl were added. Again mixed on a personal vortex for 20 seconds and removed to a dark place. Cell suspension was incubated at room temperature for 15 minutes. After incubation, fluorescence was measured on a flow cytometer. If the amount of CD13+ cells in the urine sediment is less than or equal to 3 % and the number of CD45+ cells is less than or equal to 4 %, the risk of relapse is low. If the amount of CD13+ cells in the urine sediment exceeds 4% and the number of CD45+ cells exceeds 6 %, the risk of recurrence is high.

EFFECT: invention allows to assess the risk of developing a recurrence of superficial bladder cancer after surgical treatment.

1 cl, 2 tbl, 2 ex